|

NK520 Clinical Trials

2 actively recruiting trials

Also known as: genetic modified NK cell

Pipeline

Early 1: 2

Top Sponsors

  • Base Therapeutics (Shanghai) Co., Ltd.2

Indications

  • Relapsed/Refractory Acute Myeloid Leukemia2
  • Cancer2

Other2 trials

Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia
Early 1
Safety and Efficacy of NK520 to Treat Relapsed/Refractory Acute Myeloid Leukemia
Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.